Physician profile
David H Witty
NPI 1114984374
$6,531.25
in general payments reported to CMS, 2019-2025
36 companies · $20.82 in 2025
The $20.82 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,255 · 2020: $202 · 2021: $889 · 2022: $1,630 · 2023: $1,389 · 2024: $1,145 · 2025: $20.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,331.93 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,234.25 | 2019-2024 | Fasenra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $688.02 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $413.34 | 2019-2024 | Arikayce |
| Novartis Pharmaceuticals Corporation | $263.54 | 2021-2024 | |
| Harmony Biosciences LLC | $261.52 | 2020-2024 | Wakix |
| Mallinckrodt Hospital Products INC. | $216.50 | 2020-2024 | Acthar |
| Genentech USA, INC. | $190.81 | 2019-2023 | Xolair |
| Merck Sharp & Dohme LLC | $188.58 | 2019-2024 | Recarbrio, Zerbaxa, Keytruda |
| Genzyme Corporation | $184.77 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $183.04 | 2019-2024 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $148.64 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $134.08 | 2019-2024 | |
| Mylan Specialty L.P. | $117.57 | 2019-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $107.60 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $103.45 | 2021-2024 | Dupixent |
| Ani Pharmaceuticals, INC. | $98.38 | 2023-2024 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $95.44 | 2022-2024 | Glassia |
| Mallinckrodt Enterprises LLC | $67.76 | 2019 | |
| Astellas Pharma US INC | $60.25 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $53.02 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $50.51 | 2019-2020 | |
| Medtronic, INC. | $44.00 | 2023 | Illumisite |
| Pulmonx Corporation | $39.46 | 2023-2024 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Philips North America LLC | $35.01 | 2024 | (Ak6) Vest Therapy |
| Amgen INC. | $30.34 | 2023-2024 | Tezspire |
| Gilead Sciences, INC. | $28.68 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $21.16 | 2019 | |
| Electromed, INC. | $20.82 | 2025 | Smartvest |
| United Therapeutics Corporation | $20.55 | 2022 | |
| Ambu INC. | $18.88 | 2022 | |
| Pfizer INC. | $18.83 | 2024 | |
| Allergan, INC. | $16.89 | 2019 | |
| Aerin Medical INC. | $16.74 | 2022 | |
| Grifols USA, LLC | $14.44 | 2022 | |
| Monaghan Medical Corporation | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Witty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.